XBiotech Inc
For the period ended Dec 31, 2023. Filed Mar 15, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 15, 2024
XBIT$1.91+1.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Shareholders’ Equity
| Number of Shares · Common Stock Amount · Accumulated Other Comprehensive Income · Retained Earnings (Accumulated deficit) · Total | ||||||
|---|---|---|---|---|---|---|
| Balance at December 31, 2021 | 30,439 | $262,263 | $1,971 | $5,151 | $269,385 | |
| Net loss | - | - | - | (32,900) | (32,900) | |
| Foreign currency translation adjustment | - | - | 422 | - | 422 | |
| Realized comprehensive income | - | - | (1,567) | - | (1,567) | |
| Share-based compensation expense | - | 5,062 | - | - | 5,062 | |
| Balance at December 31, 2022 | 30,439 | 267,325 | 826 | (27,749) | 240,402 | |
| Net loss | - | - | - | (24,557) | (24,557) | |
| Tender offer | (4) | (14) | - | - | (14) | |
| Foreign currency translation adjustment | - | - | (252) | - | (252) | |
| Reclassification of deferred tax assets | - | 574 | (574) | - | - | |
| Issuance of common stock under stock option plan | 1 | 5 | - | - | 5 | |
| Share-based compensation expense | - | 3,262 | - | - | 3,262 | |
| Balance at December 31, 2023 | 30,436 | $271,152 | $ | - | $(52,306) | $218,846 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.